Market Overview

Wedbush Securities Reiterates Outperform Rating, $102 PT on Humana

Share:
Related HUM
Humana To Begin Covering Exact Science's Cologuard In 2017
Benzinga's Top Downgrades
Valuation Dashboard: Healthcare - Update (Seeking Alpha)

In a report published Wednesday, Wedbush Securities reiterated its Outperform rating and $102.00 price target on Humana (NYSE: HUM).

Wedbush Securities noted, “Budget headwinds could weigh on the group through year end, but ultimately we believe volume growth outweighs rate risks. The group historically comes under pressure in times of regulatory uncertainty, we view the grand bargain budget scenario as presenting more uncertainty than sequestration, but view both as manageable risks from an operational standpoint. We believe Humana has several levers to pull to maintain 5% margins in the face of rate pressure, but even under a bear-case (an unlikely in our opinion) 3% margin scenario we believe volume growth will more than outweigh the margin compression by 2015.”

Humana closed on Tuesday at $68.29.

Latest Ratings for HUM

DateFirmActionFromTo
Dec 2016Cantor FitzgeraldDowngradesBuyHold
Nov 2016Credit SuisseUpgradesNeutralOutperform
Nov 2016JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!